First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis - Laleu, B; Gaggini, F; Orchard, M; Fioraso-Cartier, L; Cagnon, L; Houngninou-Molango, S; Gradia, A; Duboux, G; Merlot, C; Heitz, F; Szyndralewiez, C; Page, P (J Med Chem, 2010)